Clinical Trials/Observational Studies
Clinical trials play a critical role in advancing medical knowledge and improving patient outcomes. They help to test new treatments, therapies, and medical devices, and provide valuable insights into the safety and effectiveness of these interventions.
VASCERN is a network of highly specialized healthcare providers and experts in the field of rare multisystemic vascular diseases, dedicated to improving the diagnosis, management, and treatment of these complex conditions. Through our collaborations with researchers, patient organizations, and industry partners, we strive to identify and develop innovative solutions that can benefit patients with rare vascular diseases.
This page provides up-to-date information on ongoing and upcoming clinical trials in VASCERN.
Hereditary Hemorrhagic Telangiectasia (HHT-WG)
The SAIPAN-trial is a multicenter, randomized, open-label, parallel group, superiority trial with Danish, French, Italian and Netherlands HCPs participating. It is a study to evaluate the effectiveness of Somatostatin Analogues in Patients with hereditary hemorrhagic telangiectasia and symptomatic gastrointestinal bleeding.
Vascular Anomalies (VASCA-WG)
The VASCA-WG currently has one clinical trial underway: The VASE (Vascular Anomaly-Sirolimus Europe). It is a phase III multicentric study evaluating the efficacy and safety of sirolimus in Vascular Anomalies that are refractory to standard care.